Truist downgraded BioXcel Therapeutics to Hold from Buy without a price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BTAI:
- BioXcel Therapeutics provides update on recent developments for IGALMI
- BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (dexmedetomidine) Sublingual Film
- Short Report: Bears reduce exposure to Nordstrom amid selloff
- Biotech Alert: Searches spiking for these stocks today
- BioXcel Therapeutics price target lowered to $11 from $60 at H.C. Wainwright